Beyond progression-free survival (PFS): time to next treatment (TTNT) as a patient-centered metric of clinical benefit in chronic lymphocytic leukemia (CLL).

INTRODUCTION: In chronic lymphocytic leukemia (CLL), progression-free survival (PFS) remains a fundamental efficacy endpoint; however, it does not fully capture patient-centric measures such as treatment discontinuation or adherence. Time to next tre…

Preview only. Read the full abstract at the source